Voyager Therapeutics, Inc.

Good morning and welcome to Voyager Therapeutics' 2022 Fourth Quarter and ERA Conference Call. All participants are now in listen-only mode. There will be a question and answer session at the end of this call. Please be advised this call is being recorded at the company's request. A replay of today's call will be available on the investor section of the company's website approximately two hours after completion of this call. I would now like to turn the call over to Pete Frenshue, Chief Financial Officer.

Thank you and good morning.

Joining me on today's call are Dr. Al Stanrock, our CEO, Dr. Todd Carter, our Chief Scientific Officer, and Alan Nunley, our Chief Business Officer. We issued our Q4 and year-end 2022 press release this morning. The press release and 10-K are available on our website. We plan to provide a brief summary of key highlights from the quarter and reserve the majority of time for your Q&A. In a moment, I will turn the call over to Al. Before I do this, I want to remind everyone that during this call, Voyager representatives may make forward-looking statements regarding future expectations, plans, and prospects. All forward-looking statements are inherently uncertain and are subject to risks and uncertainties that may cause actual results to differ materially from those indicated by these forward-looking statements. You are encouraged to review and understand the number of the material risks and uncertainties facing the company as described in the company's annual report on Form 10-K filed with the SEC this morning. All SEC filings are available on the company's website. Now it is my pleasure to turn the call over to Al.